Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Obsessive Compulsive Disorder
Conditions
Obsessive Compulsive Disorder
Trial Timeline
May 1, 2007 → Apr 1, 2010
NCT ID
NCT00466609About Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)
Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo) is a approved stage product being developed by Novartis for Obsessive Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00466609. Target conditions include Obsessive Compulsive Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00466609 | Approved | Completed |
Competing Products
17 competing products in Obsessive Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine | Eli Lilly | Approved | 85 |
| Fluvoxamine maleate + Placebo | AbbVie | Phase 3 | 77 |
| quetiapine fumarate + SSRI/Clomipramine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 52 |
| sertraline | Pfizer | Pre-clinical | 22 |
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram | Lundbeck | Approved | 82 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| RG1068 (Synthetic Human Secretin) | Repligen | Phase 2 | 49 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 60 |
| Troriluzole (BHV-4157) | Biohaven | Phase 3 | 72 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |